Ambio’s new clinical program offers access to ibogaine for people with Parkinson’s, MS, and other neurodegenerative and medically complex conditions. Soft-launched in February 2025, Ambio’s ...
BEECH ISLAND, S.C.--(BUSINESS WIRE)--Ambio, Inc., an innovative biotech company developing novel peptide drugs, biosimilar, bioequivalent, and other complex generic drugs, announced today that a ...
Ambio announced that a generic version of Forteo (teriparatide injection) developed by Ambio and to be marketed and sold by Apotex has been approved by the Food and Drug Administration. Forteo ...
Vancouver, British Columbia, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ambio Life Sciences, the global leader in integrative ibogaine treatment, today announced the opening of its newest clinic in Malta – ...
North Augusta, South Carolina, USA and Shanghai, China – Global alternative asset manager The Carlyle Group (NASDAQ: CG) today announced that it has acquired a significant minority stake in Ambio ...
Vancouver, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- Ambio Life Sciences , the global leader in integrative ibogaine treatment, has announced the launch of the world's first clinical ...
Partner Apotex Corp. (Apotex) to market and sell to the U.S. healthcare market BEECH ISLAND, S.C.--(BUSINESS WIRE)--Ambio, Inc., an innovative biotech company developing novel peptide drugs, ...
Ambio Malta sets a new standard for ibogaine care in Europe, where no physician-led clinics currently operate. Meeting global demand for safe treatment, the clinic expands Ambio’s capacity while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results